Abstract
Altogether 107 patients were operated on at the Department of Transplantation and Surgery of Semmelweis University in the past four years, for clinical symptoms of hyperparathyroidism. Clinical and laboratory data of the patients supported the diagnosis of primary or secondary hyperparathyroidism. Chronically impaired renal function was found in 52 cases. The removed parathyroid glands showed hyperplasia in 54, adenoma in 50 and carcinoma in 3 cases. The majority of parathyroid lesions in primary hyperparathyroidism were adenomas (41 cases) and in secondary hyperparathyroidism were hyperplasias (43 cases). The ratio of oxyphil to chief cells as well as occasional mitotic and apoptotic figures were determined. The oxyphil component was present in both hyperplastic and tumorous lesions. Apoptosis and mitosis were rarely seen in hyperplasias and adenomas (under 2%), whereas in carcinomas 3% of the tumor cells were apoptotic and 4% showed mitosis. Cytoplasmic p53 positivity could be observed in 3 of the adenomas and in 2 of the hyperplasias. The carcinomas, four adenomas and 3 hyperplasias showed nuclear p53 positivity. Bcl-2 and Bax were detected in the cytoplasm of the tumor cells in the majority of adenomas and in the cells of hyperplasias. Oxyphil cells were more frequently positive than chief cells or clear cells. Colocalization of Bcl-2 and Bax was found randomly in all types of lesions. The very low incidence of carcinoma, the low mitotic and apoptotic ratio in adenomas and hyperplasias suggest a potent antiproliferative defense mechanism in the parathyroid cell population. This may also be reflected in the cytoplasmic colocalization of various gene products which regulate cell death and cell proliferation. No significant differences in the p53, Bcl-2 and Bax spectrum were found between the primary and secondary (i.e. renal failure) parathyroid alterations.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Roth SJ: The parathyroid gland. In Silverberg, S G.Principals and practice of surgical pathology. Second edition. Churchill Livingstone, New York, pp; 1923–1955, 1990
Reiss E, Counterbury IM. Spectrum of hyperparathyroidism. Am J Med 56: 784–810, 1974
Koea JB, Shaw JH: Parathyroid cancer: Biology and management. Surg Oncol 8:155–165, 1999
Bocsi J, Perner F, Szücs J, et al: DNA content of parathyroid tumors, Anticancer Res 18: 2901–2904, 1998
Ricci F, Mingazzini PL, Sebastiani V, et al: P53 as a marker of differentiation between hyperplastic and adenomatous lesions of parathyroids. Int Diag Pathol 6:229–235, 2002
Stojadinovic A, Hoos A, Nissan A, et al: Cordon-Cardo C, Shaha AR, Brennan MF, Singh B, Gossein RA. Parathyroid neoplasms: Clinical, histopathological, and tissue microarraybased molecular analysis. Hum Pathol 34: 54–64, 2003
Abbona GC, Papotti M, Gasparri G, et al: Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol 26: 135–138, 1995
Vargas MP, Vargas HI, Kleiner DE, et al: The role of prognostic markers (MIB-1, RB, and Bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol 10: 12–17, 1997
Erikson LA, Jin L, Wollan P, et al: Parathyroid hyperplasia, adenomas and carcinomas: Differential expression of P27 protein. Am J Surg Pathol 23: 288–295 1999
Schantz A, Castleman B: Parathyroid carcinoma: A study of 70 cases. Cancer 31: 600–605, 1973
Snover DC, Foukar K: Mitotic activity in benign parathyroid disease. Am J Clin Pathol 75: 355–347, 1981
Zang Y, Xiong Y: P53 amino terminal nuclear signal inhibited by DNA damage-induced phosphorylation. Science 292: 1910–1915, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Szende, B., Farid, P., Végső, G. et al. Apoptosis and p53, Bcl-2 and bax gene expression in parathyroid glands of patients with hyperparathyroidism. Pathol. Oncol. Res. 10, 98–103 (2004). https://doi.org/10.1007/BF02893463
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02893463